Biotech Specialty Pharma


13 Stonebrook Court
Harrington Park, New Jersey 07640 USA
Click for website

Research Sector Biotech Specialty Pharma

Summary Description Designs, patents, and commercializes devices and therapeutics for back pain.

Management Peter A. Zahos, MD, CEO; Marvin A. Collin, VP of Development

Click here for Financial Data
Keywords: Orthopedics, DPI, Back, PainManagement


Updated: Mar. 23, 2016


Discogen targets the biological processes associated with inflammation and degradation of the intervertebral disc through topical and minimally invasive strategies. Discogen devices and therapies will......view more

Products / Services

Discogen currently holds two patent protected device and therapy intervention technologies which provides unique alternatives to invasive spine surgery. The Discogen Injectable Hydrogel will focus on......view more

Technology / Differentiation

Discogen has a proprietary technology for the utilization of a hydrogel complex that can act as an annular sealant as well as nucleus filler that can target the etiology of DBP mechanically. Working i...view more

Market / Customers

The American Academy of Orthopaedic Surgeons estimates that more than 6 million people are diagnosed with Discogenic Back Pain (DBP) annually, with 80% of the US population experiencing DBP sometime i......view more


The Dicogen CEO, Peter A. Zahos MD, is a board-certified neurosurgeon and Fellow of the American College of Surgeons and former Chairman of the Department of Neurosurgery at Cleveland Clinic Florida. ...view more


Currently the Discogen is seeking an investment of 3 million (US) to fund the development of the Discogen Ultra-Sound Generator, Hydrogel Delivery System and pilot human clinical studies, in- coordina...view more